Latest Strategy News

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Cann Group Limited reported a 34% rise in dried flower production and doubled Botanitech brand flower sales in FY25, while cutting operating expenses by 35%. The company is targeting an EBITDA-positive FY26 amid ongoing debt restructuring.

xReality Group (XRG) reports a landmark FY25 with 36% revenue growth driven by its Operator XR platform and a major US law enforcement contract. The company’s strategic shift towards immersive training technology signals robust momentum into FY26.

Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.

Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.

ECS Botanics reports a 5% revenue dip to $19.5 million in FY25 but sees strong B2C growth and record harvest volumes, offset by non-cash impairments.

ECS Botanics Holdings Ltd reported a $5.7 million net loss for FY2025 amid a strategic pivot from B2B to B2C sales and significant impairments. The company aims for a turnaround in FY2026 driven by new product launches and expanded production capacity.

Aspermont Limited invites existing shareholders to participate in a $1.25 million Share Purchase Plan at a premium price, supporting its pivot to data-driven intelligence services and a strategic Rio Tinto partnership.

Tissue Repair Ltd reported a 27.3% revenue increase to $3.22 million for FY25, driven by new distribution deals and regulatory progress, while continuing to invest heavily in clinical trials and manufacturing scale-up, resulting in a $4.24 million loss.

Axiom Properties Limited reports a 55% reduction in net loss for FY25, completing its Glenlea Estate sales and accelerating its Property Technology strategy with a $30 million debt facility for PaySure.

Pengana Global Private Credit Trust (PCX) has delivered a solid first-year performance, achieving an 8.41% total return driven by a 7.04% cash yield and NAV growth. The Trust also increased monthly distributions and declared a special payout, underscoring its commitment to stable income and capital preservation.